Douglas Levine, MD, discusses a recent study in uterine carcinosarcoma and early steps toward developing therapeutic regimens.
John E. Mullinax, MD, discusses isolated limb infusion as a limb salvage strategy for locally advanced extremity sarcoma.
Brian Van Tine, MD, PhD, discusses the potential of the investigational compound 5-imino-13-deoxydoxorubicin (GPX-150) in metastatic and nonresectable soft tissue sarcoma.
Markus Albertsmeier, MD, discusses the results of the meta-analysis and the implications going forward for the treatment of patients with soft tissue sarcoma.
An immunohistochemistry analysis of a large patient population demonstrated that several subtypes of difficult-to-treat sarcomas may respond to treatment with PD-1 pathway inhibiting immunotherapies, according to findings presented at the 2017 European Cancer Congress in Amsterdam.
Researchers are hoping the immunotherapy revolution occurring across several cancer types will extend to the field of sarcoma.
According to Dimosthenis Andreou, MD, patients with pelvic Ewing sarcoma have poorer local control and poorer overall survival.
According to Nancy Gordon, MD, immunotherapy stands to play a critical role in the treatment of patients with osteosarcoma and lung metastases.
Excitement continues to surround the potential role of immunotherapy agents in the treatment of patients with sarcoma, according to Breelyn Wilky, MD.
Several challenges remain in the treatment landscape of soft tissue sarcoma, a disease whose diagnosis can range from one that is quite indolent for patients, to a more life-threatening, metastatic, aggressive cancer.